Egypt 2017b.

Trial name or title	Use of sildenafil citrate in management of mild pre‐eclampsia. ClinicalTrials.gov Identifier: NCT03262961.
Methods	Double‐blinded, randomised, placebo‐controlled trial.
Participants	Target: 80 women Uncomplicated mild pre‐eclampsia at 28 to 36 weeks' gestation with singleton viable pregnancy (age: 18 to 35 years).
Interventions	Treatment arm: sildenafil citrate (Respatio® 20 mg tablets manufactured by Pharma Right Group, Egypt) divided into 3 doses per day (every 8 hours) till termination of pregnancy. Control arm: a placebo drug that has the same shape, size and colour but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
Outcomes	Primary outcomes: gestational age at time of termination and progression to severe pre‐eclampsia. Secondary outcomes: neonatal survival, birthweight, Apgar score at 1 and 5 minutes and direct postnatal need to NICU, maternal BP, method of termination of pregnancy, side‐effects (headache, flushing and dyspepsia), evaluation of the effect of sildenafil citrate on the feto‐maternal circulation through the Doppler ultrasound.
Starting date	September 15, 2016
Contact information	Contact: Fady Abdallah (00201002837042) fady.nasif@yahoo.com Contact: Hisham Abou‐Taleb (00201003332139) hishamaboutaleb1@yahoo.com Assiut University.
Notes	Ongoing.